NCT04801017View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

PHASE2UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

August 31, 2021

Study Completion Date

October 31, 2021

Conditions
COVID-19
Interventions
DRUG

OT-101

TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide

DRUG

Artemisinin

Herbal Supplement/ Purified extract from Artemisia

DRUG

Placebo

0.9% sodium chloride injection

Trial Locations (1)

Unknown

Praxis Pesquisa Medica S / S Ltda, Jardim

Sponsors

Lead Sponsor

Oncotelic Inc.
All Listed Sponsors
lead

Oncotelic Inc.

INDUSTRY